Buy this article for $7.95

Have a coupon or promotional code? Enter it here:

When you buy this article you'll get access to the ePub version, a downloadable PDF, and the ability to print the full article.


Oncology Times

September 2012, Volume 34 Number 18 , p 16 - 17


  • Mark Fuerst


CHICAGO-Smart drug combinations that target specific pathways provide hope for hormone receptor-positive (HR2+) advanced breast cancer patients whose disease has failed to respond or become refractory to endocrine therapy, with active second-generation combinations waiting in the wings. The following is a roundup of such approaches reported at this year's ASCO Annual Meeting.The combination of the aromatase inhibitor (AI) exemestane and the inhibitor of mammalian target of rapamycin (mTOR) signaling pathway everolimus showed significant improvement in progression-free survival (PFS)."We now have new novel treatments for HR-positive breast cancer patients," Denise Yardley, MD, Senior Investigator in the Breast Cancer Research Program at Sarah Cannon Research Institute, said in an interview.The updated data from the BOLERO-2 trial confirm that exemestane combined with everolimus delays time without tumor growth for women with ER2-positive advanced breast cancer. She also pointed to the investigational agent trastuzumab emtansine, the combination of a monoclonal antibody and a cytotoxic drug, as promising for this patient population."The options for these patients have been limited. About half of them do not respond to initial treatment with endocrine therapy, and almost all initial responders develop resistance," she said.Stephen Johnston, MA, PhD, Professor of Breast Cancer Medicine and Director of Clinical Research and Development at the Royal Marsden and the Institute of Cancer Research in London, said, "The BOLERO-2 trial told us these types of combinations can be effective. Newer drug combinations may be better, more specific inhibitors."He predicted that other BOLERO-2-like studies will show more advances with AIs since mTOR appears to be the dominant pathway in endocrine therapy-refractory patients.At the ASCO meeting, Martine Piccart-Gebhart, MD, PhD, Head of the Medicine Department at Institut Jules Bordet in Brussels, Belgium, presented an 18-month analysis

To continue reading, buy this article for just $7.95.

Have a coupon or promotional code? Enter it here: